Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RT-054: A Phase I Study of Neoadjuvant Hypofractionated Chemoradiation Plus Radiosurgical Boost for Patients With Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer

NCT01739439 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT01739439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01739439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RT-054: A Phase I Study of Neoadjuvant Hypofractionated Chemoradiation Plus Radiosurgical Boost for Patients With Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2013
Completion date
December 1, 2015
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acinar cell adenocarcinoma of the pancreas, duct cell adenocarcinoma of the pancreas, stage iib pancreatic cancer, stage iii pancreatic cancer